A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.

OBJECTIVE We evaluated the efficacy and toxicity of combined paclitaxel and cisplatin chemotherapy in patients with cancer of unknown primary site (CUP). Efficacy was evaluated in terms of response rate, progression-free survival and overall survival. METHODS Thirty-seven patients with CUP were enrolled between January 2001 and September 2003 at Korea… CONTINUE READING